{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T07:27:43Z","timestamp":1787038063305,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,18]]},"DOI":"10.7759\/cureus.114704","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T07:05:52Z","timestamp":1787036752000},"source":"Crossref","is-referenced-by-count":0,"title":["Striking Discordance Between Morphological Residual Disease and Histological Pathological Complete Response: A Case Report of Pembrolizumab Treatment in Mismatch Repair-Deficient Colorectal Cancer With Liver Metastases"],"prefix":"10.7759","author":[{"given":"Kohei","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuki","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Taketomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le DT","year":"2015","unstructured":"Le DT, Uram JN, Wang H, et al.. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015, 372:2509-20. 10.1056\/NEJMoa1500596","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.888181","article-title":"Microsatellite instability and metastatic colorectal cancer - a clinical perspective","volume":"12","author":"Buchler T","year":"2022","unstructured":"Buchler T. Microsatellite instability and metastatic colorectal cancer - a clinical perspective. Front Oncol. 2022, 12:888181. 10.3389\/fonc.2022.888181","journal-title":"Front Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9 T","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, et al.. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020, 383:2207-18. 10.1056\/NEJMoa2017699","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa052","article-title":"Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer","volume":"113","author":"Ludford K","year":"2021","unstructured":"Ludford K, Cohen R, Svrcek M, et al.. Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer. J Natl Cancer Inst. 2021, 113:208-11. 10.1093\/jnci\/djaa052","journal-title":"J Natl Cancer Inst"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.06.008","article-title":"Nivolumab\u00a0plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142","volume":"33","author":"Andr\u00e9 T","year":"2022","unstructured":"Andr\u00e9 T, Lonardi S, Wong KY, et al.. Nivolumab\u00a0plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol. 2022, 33:1052-60. 10.1016\/j.annonc.2022.06.008","journal-title":"Ann Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer","volume":"390","author":"Chalabi M","year":"2024","unstructured":"Chalabi M, Verschoor YL, Tan PB, et al.. Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. N Engl J Med. 2024, 390:1949-58. 10.1056\/NEJMoa2400634","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2022.2054289","article-title":"Complete pathologic response (pCR) following neoadjuvant pembrolizumab monotherapy in treatment-naive locally advanced, mismatch repair protein-deficient (dMMR) colonic cancer: a case report and literature review","volume":"61","author":"Tan-Garcia A","year":"2022","unstructured":"Tan-Garcia A, Wang LM, Ngu JC, Goh L. Complete pathologic response (pCR) following neoadjuvant pembrolizumab monotherapy in treatment-naive locally advanced, mismatch repair protein-deficient (dMMR) colonic cancer: a case report and literature review. Acta Oncol. 2022, 61:780-4. 10.1080\/0284186X.2022.2054289","journal-title":"Acta Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1466497","article-title":"Pathological response following neoadjuvant immunotherapy and imaging characteristics in dMMR\/MSI-H locally advanced colorectal cancer","volume":"15","author":"Deng Z","year":"2024","unstructured":"Deng Z, Luo Y, Chen X, et al.. Pathological response following neoadjuvant immunotherapy and imaging characteristics in dMMR\/MSI-H locally advanced colorectal cancer. Front Immunol. 2024, 15:1466497. 10.3389\/fimmu.2024.1466497","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.23922\/jarc.2019-018","article-title":"Japanese classification of colorectal, appendiceal, and anal carcinoma: the 3D English edition (secondary publication)","volume":"3","author":"Japanese Society for Cancer of the Colon and Rectum","year":"2019","unstructured":"Japanese Society for Cancer of the Colon and Rectum. Japanese classification of colorectal, appendiceal, and anal carcinoma: the 3D English edition (secondary publication). J Anus Rectum Colon. 2019, 3:175-95. 10.23922\/jarc.2019-018","journal-title":"J Anus Rectum Colon"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01351","article-title":"Neoadjuvant pembrolizumab in localized microsatellite instability high\/deficient mismatch repair solid tumors","volume":"41","author":"Ludford K","year":"2023","unstructured":"Ludford K, Ho WJ, Thomas JV, et al.. Neoadjuvant pembrolizumab in localized microsatellite instability high\/deficient mismatch repair solid tumors. J Clin Oncol. 2023, 41:2181-90. 10.1200\/JCO.22.01351","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1680500","article-title":"Discordance between radiological and pathological response to neoadjuvant immunotherapy in mismatch repair-deficient\/microsatellite instability-high colorectal cancer: a meta-analysis","volume":"17","author":"Xie Y","year":"2026","unstructured":"Xie Y, Liao L, Ding P, Jiang W. Discordance between radiological and pathological response to neoadjuvant immunotherapy in mismatch repair-deficient\/microsatellite instability-high colorectal cancer: a meta-analysis. Front Immunol. 2026, 17:1680500. 10.3389\/fimmu.2026.1680500","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2376","article-title":"Do we need a different set of response assessment criteria for tumor immunotherapy?","volume":"15","author":"Ribas A","year":"2009","unstructured":"Ribas A, Chmielowski B, Glaspy JA. Do we need a different set of response assessment criteria for tumor immunotherapy?. Clin Cancer Res. 2009, 15:7116-8. 10.1158\/1078-0432.CCR-09-2376","journal-title":"Clin Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15024","article-title":"(18) F-FDG PET\/CT predicts the role of neoadjuvant immunochemotherapy in the pathological response of esophageal squamous cell carcinoma","volume":"14","author":"Wang S","year":"2023","unstructured":"Wang S, Di S, Lu J, Xie S, Yu Z, Liang Y, Gong T. (18) F-FDG PET\/CT predicts the role of neoadjuvant immunochemotherapy in the pathological response of esophageal squamous cell carcinoma. Thorac Cancer. 2023, 14:2338-49. 10.1111\/1759-7714.15024","journal-title":"Thorac Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113483","article-title":"Impact of PET\/CT for assessing response to immunotherapy - a clinical perspective","volume":"9","author":"Lang D","year":"2020","unstructured":"Lang D, Wahl G, Poier N, Graf S, Kiesl D, Lamprecht B, Gabriel M. Impact of PET\/CT for assessing response to immunotherapy - a clinical perspective. J Clin Med. 2020, 9:3438. 10.3390\/jcm9113483","journal-title":"J Clin Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8622","article-title":"Wait-and-see treatment strategies for rectal cancer patients with clinical complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis","volume":"7","author":"Li J","year":"2016","unstructured":"Li J, Li L, Yang L, Yuan J, Lv B, Yao Y, Xing S. Wait-and-see treatment strategies for rectal cancer patients with clinical complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. Oncotarget. 2016, 7:44857-70. 10.18632\/oncotarget.8622","journal-title":"Oncotarget"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30074-2","article-title":"A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis","volume":"2","author":"Dossa F","year":"2017","unstructured":"Dossa F, Chesney TR, Acuna SA, et al.. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017, 2:501-13. 10.1016\/S2468-1253(17)30074-2","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye ES","year":"2022","unstructured":"Husebye ES, Castinetti F, Criseno S, et al.. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022, 187:G1-21. 10.1530\/EJE-22-0689","journal-title":"Eur J Endocrinol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/510395-striking-discordance-between-morphological-residual-disease-and-histological-pathological-complete-response-a-case-report-of-pembrolizumab-treatment-in-mismatch-repair-deficient-colorectal-cancer-with-liver-metastases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T07:05:52Z","timestamp":1787036752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/510395-striking-discordance-between-morphological-residual-disease-and-histological-pathological-complete-response-a-case-report-of-pembrolizumab-treatment-in-mismatch-repair-deficient-colorectal-cancer-with-liver-metastases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.114704","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}